Psychometric properties of the Greek version of Affective Lability Scale - Short Form (ALS-18) in a sample of adults with neurodevelopmental disorders.

Affect dysregulation refers to maladaptive patterns of emotional regulation that impair daily life functioning, common in many psychiatric disorders. It is expressed with the form of affective lability, an emotional construct composed of frequent and intense fluctuations in emotion in response to both pleasant and unpleasant events or the interpretations of events. The Affective Lability Scale (ALS) is a widely used self-reporting questionnaire that measures the tendency of emotions to shift from one to another as well as their tendency to oscillate between depression and elation and between depression and anxiety. The original scale had 54 items, but a shorter form of 18-items (ALS-18) was created, with three domains: anxiety-depression shift, depression-elation shift and anger shift. The aim of the present study was to evaluate the psychometric properties of the ALS-18 Greek version. The translation was conducted by two of the authors. The study took place in the 1st Department of Psychiatry of the National and Kapodistrian University of Athens, Eginition hospital. A sample of 108 adults was included in the survey in two groups, neurodevelopmental disorder group (attention deficit hyperactivity disorder or autism spectrum disorder) and controls. They all completed ALS-18, The State - Trait Anxiety Inventory (STAIT), Difficulties in Emotion Regulation Scale (DERS), The Hospital Anxiety and Depression Scale (HADS). The ALS-18 had satisfactory internal consistency; Cronbach's α value was 0.91 for the total scale and 0.89 for Anxiety/Depression, 0.86 for Depression/Elation and 0.85 for Anger. The three-factor structure was replicated in our data. The internal consistency reliability of all the ALS-18 factors in our study could be considered satisfactory with a Cronbach's alpha coefficient of 0.85 or above for all factors. Significantly higher mean values were found for all the subscales, Anxiety/Depression, Depression/Elation and Anger, in NDD subjects as compared to controls, showing good discriminative ability. The ALS factors discriminated well between clinical and non-clinical sample. The present study reveals that the Greek version of ALS-18 presents good psychometric properties, showing good internal consistency reliability as well as concurrent and discriminative validity. It has an elevated score in NDD and thus, our results indicate that affective lability could and maybe should, be a target integrated in therapeutic strategies.

Trait-Based Dimensions Discriminating Adults with Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and, Co-occurring ADHD/ASD.

This study assessed the co-occurrence of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in newly diagnosed adults of normal intelligence and the contribution of trait-based dimensions deriving from the Barkley Adult ADHD Rating Scale-IV (BAARS-IV), the Autism-Spectrum Quotient (AQ), and the Empathy Quotient (EQ) to the differentiation of patients with ADHD, ASD, and ADHD/ASD. A total of 16.1% of patients with ADHD received a co-occurring ASD diagnosis, while 33.3% of patients with ASD received an ADHD diagnosis. Subjects with ADHD or ADHD/ASD had higher scores in all ADHD traits compared to ASD subjects. Compared to the ADHD group, the ASD group had AQ scores that were significantly greater, except for attention to detail. ADHD/ASD co-occurrence significantly increased the score of attention to detail. The total EQ score was greater in the ADHD group. In the stepwise logistic regression analyses, past hyperactivity, current inattention and impulsivity, attention switching, communication, imagination, and total EQ score discriminated ADHD patients from ASD patients. Attention to detail, imagination, and total EQ score discriminated ADHD cases from ADHD/ASD cases, while past hyperactivity and current impulsivity discriminated ASD subjects from ADHD/ASD subjects. Our findings highlight the importance of particular trait-based dimensions when discriminating adults with ADHD, ASD, and co-occurring ADHD/ASD.

Lifetime co-occurring psychiatric disorders in newly diagnosed adults with attention deficit hyperactivity disorder (ADHD) or/and autism spectrum disorder (ASD).

BACKGROUND: Co-occurring psychiatric disorders in adults with Attention Deficit Hyperactivity Disorder (ADHD) and/or Autism Spectrum Disorder (ASD) contribute to the burden of the healthcare and possibly to the delay of diagnosis. Aim of the study was to clinically assess the prevalence and compare lifetime co-occurring psychopathology in a sample of newly diagnosed ADHD and/or ASD adults and discuss the diagnostic challenges they pose. METHODS: The lifetime prevalence rates of ten of the most frequently co-occurring psychiatric diagnoses was registered in 336 adults of normal intelligence who underwent a thorough clinical evaluation for the diagnosis of ADHD and/or ASD for the first time in their lives. Four study groups were formed: the ADHD (n = 151), the ASD (n = 58), the ADHD+ASD (n = 28) and the nonADHD/nonASD (NN) (n = 88) group. RESULTS: At least one co-occurring psychopathology was found in 72.8% of the ADHD group, in 50% of the ASD group, in 72.4% of the ADHD+ASD group and in 76.1% of the NN group (p = 0.004). In all groups the most frequent psychiatric disorder was depressive disorder. The only significant difference regarding the patterns of psychiatric co-occurrence between the ADHD and the nonADHD groups (ASD and NN groups) was found for SUD (p = 0.001). Also, the proportion of subjects with Bipolar Disorder was significantly greater in the NN group as compared to those with ASD (p = 0.025). CONCLUSIONS: Our results support the high prevalence of co-occurring psychiatric disorders in adults with ADHD and/or ASD with the ASD group presenting the lowest rate. The most marked difference between the ADHD and the nonADHD groups was found for SUD. Moreover, our findings highlight the need for a thorough clinical assessment of all referred patients both in the presence and absence of ADHD and/or ASD.